Urolithin A

Urolithin A

• CAS Number: 1143-70-0
• UNSPSC Description: Urolithin A, a gut-microbial metabolite of ellagic acid, exerts anti-inflammatory, antiproliferative, and antioxidant properties. Urolithin A induces autophagy and apoptosis, suppresses cell cycle progression, and inhibits DNA synthesis[1][2].
• Target Antigen: Apoptosis; Autophagy; DNA/RNA Synthesis; Drug Metabolite; Endogenous Metabolite; Reactive Oxygen Species
• Type: Natural Products
• Related Pathways: Apoptosis;Autophagy;Cell Cycle/DNA Damage;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Urolithin-A.html
• Purity: 99.82
• Solubility: DMSO : 30 mg/mL (ultrasonic)
• Smiles: O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1
• Molecular Weight: 228.20
• References & Citations: [1]Gong Z, et al. Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice.|[2]Zhao W, et al. Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620colorectal cancer cells. Mol Carcinog. 2018 Feb;57(2):193-200.|[3]Qiu Z, et al. In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol. 2013 Sep;59:428-37.|[4]González-Sarrías A, et al. Antiproliferative activity of the ellagic acid-derived gut microbiota isourolithin A and comparison with its urolithin A isomer: the role of cell metabolism.Eur J Nutr. 2017 Mar;56(2):831-841.|[5]Wang Y, et al. In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells. Toxicol In Vitro. 2015 Aug;29(5):1107-15.|[6]Ishimoto H, et al. In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5901-4.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported